COMP <GO>
RCEL vs JNJ // EV/EBITDA & P/E VALUATION
Avita Medical Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: RCEL 3
— JNJ 6
■ METRIC PARITY
LAST: $16.71 (+1.27%) • MKT CAP: $516.8M
valuation
—
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RCEL VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RCEL | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 82.10% | 67.90% | +14.20 | RCEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.23% | 2.97% | -9.20 | JNJ | /fcf-yield <GO> |
| Operating Margin | -59.40% | 34.70% | -94.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 6.00% | +5.50 | RCEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.2 | 62.1 | +4.05 | RCEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $516.8M | $662.49B | -$661.97B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RCEL REV | JNJ REV | RCEL GROSS % | JNJ GROSS % | RCEL FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $71.6M | $94.19B | 82.1% | 67.9% | -$32.2M | $19.70B |
| FY 2024 | $64.3M | $88.82B | 85.8% | 69.1% | -$58.1M | $19.84B |
| FY 2023 | $50.1M | $85.16B | — | — | -$38.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RCEL // BETA —
JNJ // BETA 1.08